Zhaoke Ophthalmology Ltd 2021 SR
The report highlights Zhaoke Ophthalmology's commitment to sustainable development in the biotech industry, focusing on its drug pipeline of 25 candidates for major ocular indications. In 2021, the Group established an ESG framework, including a Climate Change Policy and environmental targets for emission reduction. Key achievements include expanding the reporting boundary to include its Nansha manufacturing facility and Hong Kong head office, conducting a materiality assessment with stakeholders, and providing extensive training to employees. The Group also demonstrated social responsibility through community donations and pandemic prevention efforts.
Company: Zhaoke Ophthalmology Ltd
Sector: Health Care
Country: China
Year: 2021
Type: SR
Pages: 46
Zhaoke Ophthalmology Ltd
ESG Report
The report highlights Zhaoke Ophthalmology's commitment to sustainable development in the biotech industry, focusing on its drug pipeline of 25 candidates for major ocular indications. In 2021, the Group established an ESG framework, including a Climate Change Policy and environmental targets for emission reduction. Key achievements include expanding the reporting boundary to include its Nansha manufacturing facility and Hong Kong head office, conducting a materiality assessment with stakeholders, and providing extensive training to employees. The Group also demonstrated social responsibility through community donations and pandemic prevention efforts.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Published
May 30, 2022
Type
Sustainability Report
Language
English, Chinese
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Workplace Fatalities
Employees